What is Happening to Patent Eligibility and What Can We Do About It? June 24, 2014 Bruce D. Sunstein Denise M. Kettelberger, Ph.D. Sunstein Kann Murphy.

Slides:



Advertisements
Similar presentations
1 1 1 AIPLA Firm Logo American Intellectual Property Law Association CLS BANK: PATENT ELIGIBILITY UNDER SECTION 101 JIPA/AIPLA Meeting By Joseph A. Calvaruso.
Advertisements

Latest Developments Patent Eligibility in the U.S. post-Bilski:
Second level — Third level Fourth level »Fifth level CLS Bank And Its Aftermath Presented By: Joseph A. Calvaruso Orrick, Herrington & Sutcliffe LLP ©
Recent Cases on Patentable Subject Matter and Patent Exhaustion Mojdeh Bahar, J.D., M.A. Chief, Cancer Branch Office of Technology Transfer National Institutes.
Orlando, Florida | Mayo v. Prometheus by:Jon M. Gibbs Lowndes, Drosdick, Doster, Kantor and Reed PA.
Diagnostics: Patent Eligibility and the Industry Perspective
How Prometheus Has Upended Patent Eligibility An Anatomy of CLS Bank v. Alice Corp. 717 F.3d 1269 (Fed. Cir. 2013)(en banc) Bruce D. Sunstein Sunstein.
1.  35 U.S.C. § 101: “Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful.
1 1 AIPLA 1 1 American Intellectual Property Law Association Patentable Subject Matter in the US AIPPI-Symposium Zeist 13 March 2013 Raymond E. Farrell.
1 Bioinformatics Practice Considerations October 20, 2011 Ling Zhong, Ph.D.
USA and Canada Updates Presentation on behalf of FICPI Douglas N. Deeth President, Communications ACTING FOR THE IP PROFESSION WORLD WIDE.
© 2011 Edwards Wildman Palmer LLP & Edwards Wildman Palmer UK LLP Patenting Methods of Medical Treatment in the United States AIPPI 2011 Forum/ExCo Peter.
PATENTABLE SUBJECTS IN THE INTERNET OF THINGS ALICIA SHAH.
11 Post-Bilski Case Law Update Remy Yucel Director, Central Reexamination Unit.
Myriad and Mayo What Went Wrong? Warren D. Woessner, J.D., Ph.D. Robin A. Chadwick, J.D., Ph.D. Schwegman Lundberg & Woessner, P.A. Minneapolis, MN
1 1 AIPLA Firm Logo American Intellectual Property Law Association CURRENT STATE OF 35 USC 101: “USPTO GUIDELINES ON PRODUCTS OF NATURE, LAWS OF NATURE,
What’s Patentable? Eduardo Quinones, Ph.D., Esq. Amy A. Dobbelaere, Ph.D.
Mayo v. Prometheus Decided March 20, 2012 Roberte Makowski, Ph.D., J.D. Hans Sauer, Ph.D., J.D.
AIPLA Biotechnology Committee Webinar: Mayo v. Prometheus: Did the Bell Toll for Personalized Medicine Patents? Prof. Joshua D. Sarnoff DePaul U. College.
More on Section 101 Patent Law Prof. Merges
Wolf, Greenfield & Sacks, P.C. | 600 Atlantic Avenue | Boston, Massachusetts | | fax | wolfgreenfield.com Recent Developments.
In re Bilski (Fed Cir. 2008) Patentable subject matter In re Bilski (Fed Cir. 2008) Patentable subject matter December 2, 2008 John King Ron Schoenbaum.
1 TC 1600 Subject Matter Eligibility Under 35 USC § 101 Andrew Wang SPE 1631 (571)
2015 AIPLA IP Practice in Europe Committee June, 2015 Phil Swain Foley Hoag LLP Boston, MA - USA The Effect of Alice v CLS Bank on patent subject matter.
1 1 1 AIPLA Firm Logo American Intellectual Property Law Association UPDATE ON SUBJECT MATTER ELIGIBILITY, CLS BANK AND ITS AFTERMATH Joseph A. Calvaruso.
1 1 AIPLA Firm Logo American Intellectual Property Law Association Myriad Guidance for Biotechnology and Chemical Practice Joerg-Uwe Szipl Griffin and.
Medical Device Partnership: USPTO Interim Eligibility Guidance Michael Cygan, USPTO June 2, 2015.
Examiner Guidelines After Alice Corp. August 21, 2014 How Much “More” is “Significantly More”?
Patentable Subject Matter and Design Patents,Trademarks, and Copyrights David L. Hecht, J.D., M.B.A, B.S.E.E.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
35 USC 101 Update Business Methods Partnership Meeting, Spring 2008 by Robert Weinhardt Business Practice Specialist, Technology Center 3600
Biotechnology/Chemical/Pharmaceutical Customer Partnership: Recent Examiner Training and Developments Under 35 USC § 101 Drew Hirshfeld Deputy Commissioner.
Patent Prosecution Luncheon March White House Patent Reform: Executive Actions Draft rule to ensure patent owners accurately record and regularly.
AIPLA Biotech Committee Annual Meeting 2011 Practice Strategies In View of Recent Case Law Developments Panel – James Kelley, Eli Lilly and Company – Ling.
Public Policy Considerations and Patent Eligible Subject Matter Relating to Diagnostic Inventions Disclaimer: Any views expressed here are offered in order.
Judicially Created Diversity in Patent Law Norman Siebrasse Professor of Law University of New Brunswick, Canada.
Patent Eligible Subject Matter: Where Are We Now? A Presentation to CPTCLA September 23, 2011 Mike Connor Alston & Bird LLP Atlanta | Brussels | Charlotte.
Impact of Myriad Decisions on Patent Eligibility of Biotechnology Inventions in Australia and the US.
Post-Prometheus Interim Examination Guidelines Daphne Lainson Smart & Biggar AIPLA 1.
Post-Bilski Patent Prosecution IP Osgoode March 13, 2009 Bob Nakano McCarthy Tétrault LLP.
Chapter 5: Patent Protection for Computer Software & Business Methods.
Disembodied Embodiments: Medical Device Strategy for PCT and Foreign Applications Bruce D. Sunstein Sunstein Kann Murphy & Timbers LLP Boston
Intellectual Property: Patent Eligible Subject Matter Prof. Peng
The Myriad Genetics Case Gregory A. (Greg) Castanias Jones Day—Washington, DC September 22,
1 1 AIPLA Firm Logo American Intellectual Property Law Association More Fun with §101 – A Prosecution Perspective for Biotechnology Derived Innovation.
1. 35 USC § 101: Statutory Requirements and Four Categories of Invention August 2015 Office of Patent Legal Administration United States Patent and Trademark.
1 1 AIPLA Firm Logo American Intellectual Property Law Association More Fun with A Prosecution Perspective on the Protection of Computer Implemented.
Mayo v. Prometheus Labs – The Backdrop June 12, 2012 © 2012, all rights reserved.
SUZANNAH K. SUNDBY Partner, Canady + Lortz LLP th Street, NW Washington, DC State of Affairs in 101 Patent Land AIPLA Corporate Practice.
Myriad The Future of DNA Claims Mercedes Meyer, Ph.D., JD AIPLA 1.
© 2012 Cooley LLP, Five Palo Alto Square, 3000 El Camino Real, Palo Alto, CA The content of this packet is an introduction to Cooley LLP’s capabilities.
What is Patentable Subject Matter? Dan L. Burk Chancellor’s Professor of Law University of California, Irvine.
Interim Guidance on Patent Subject Matter Eligibility Raul Tamayo, USPTO July 13, 2015.
Introduction The Patentability of Human Genes Is patenting human genes moral? Should it be legal? Should there be international intervention?
Surviving Subject Matter in the Post Prometheus/Myriad World Lesley Rapaport LRR Patent Law Denise M. Kettelberger Sunstein Kann Murphy & Timers LLP Carmela.
Korean Intellectual Property Office October 19, 2011 Sunhee Lee, SUGHRUE MION PLLC RECENT CASES IN BIOTECH/PHARM/CHEM & 2011 AMERICA INVENTS ACT.
Jody Blanke, Professor Computer Information Systems and Law 1.
What did Enfish V Microsoft do? Dr. Sinai Yarus©
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP AIPLA BIOTECHNOLOGY COMMITTEE WEBINAR Leslie McDonell The contents of.
Restoring the Patent System: Countering Supreme Court Attacks on What Can be Patented David Kappos Robert Armitage Bruce Sunstein Denise Kettelberger,
The Challenge of Biotech Patent Eligibility in the United States:
Alexandria, Virginia July 21, 2014
PATENTS IT.CAN Annual Meeting
9th class: Patent Protection
ChIPs Global Summit, September 15, 2016
The Mayo-Alice Dogma and Paths to Eligibility for BioPharma
Recent USPTO Developments on Subject Matter Eligibility
What Is Patentable Subject Matter. Changing Perspectives in the
Gene Patenting Connecticut Invention Convention
A tutorial and update on patentable subject matter
Presentation transcript:

What is Happening to Patent Eligibility and What Can We Do About It? June 24, 2014 Bruce D. Sunstein Denise M. Kettelberger, Ph.D. Sunstein Kann Murphy & Timbers LLP

2 The Phenomenon A recent series of Supreme Court rulings has made a wide range of patents and patent applications ineligible for patent protection These decisions significantly expand the scope of claims ineligible for patenting The rulings cover diagnostic methods, gene sequences, and computer-related inventions

3 The root of the trend: Mayo v. Prometheus, 132 S. Ct (2012) The Claims administering a thiopurine drug to a subject with a gastrointestinal disorder, determining the level of a specific metabolite of the thiopurine drug in the subject, wherein a level below a first threshold indicates a need to increase drug dosage, and wherein a level above a second threshold indicates a need to decrease drug dosage.

4 The root of the trend: Mayo v. Prometheus, 132 S. Ct (2012) The Holding The claimed subject matter is ineligible for patenting as the claimed processes fail to transform unpatentable natural laws into patent-eligible applications of those laws. Upholding the patents would disproportionately risk tying up use of the underlying natural laws, inhibiting their use in making further discoveries

5 The root of the trend: Mayo v. Prometheus, 132 S. Ct (2012) The Theory “the ‘administering’ step simply refers to the relevant audience, namely doctors who treat patients with certain diseases with thiopurine drugs” “the ‘wherein’ clauses simply tell a doctor about the relevant natural laws” the determining step “tells doctors to engage in well-understood, routine, conventional activity previously engaged in by scientists who work in the field”.

6 The root of the trend: Mayo v. Prometheus, 132 S. Ct (2012) The Analysis 1. Determine whether the claims are directed to a patent-ineligible law of nature, natural phenomenon, or abstract idea 2. If so, then search for an “inventive concept”— i.e., an element or combination of elements sufficient to “transform” the claimed abstract idea into a patent-eligible application

7 The root of the trend: Mayo v. Prometheus, 132 S. Ct (2012) Rationale The Court has “a concern that patent law not inhibit further discovery by improperly tying up the future use of laws of nature” The patent claims here “threaten to inhibit the development of more refined treatment recommendations (like that embodied in Mayo's test), that combine Prometheus' correlations with later discovered features of metabolites, human physiology or individual patient characteristics”

8 The next step: Ass'n for Molecular Pathology v. Myriad, 133 S.Ct (2013) Holding: isolated segments of genomic DNA are not eligible for patenting, because gDNA is a natural phenomenon and “separating a gene from its surrounding genetic material is not an act of invention” But preparation of complementary DNA is patent eligible, because it is not a “product of nature”

9 Draft Guidelines from the USPTO, March 2014, in the wake of Prometheus and Myriad Would render ineligible for patenting: Diagnostic tests, isolated DNA segments, many purified naturally occurring substances and mixtures thereof

10 Alice Corp. v. CLS Bank, 6/19/14 Holding The claims “are drawn to the abstract idea of intermediated settlement” [“i.e., the use of a third party to mitigate settlement risk”] “[M]erely requiring generic computer implementation fails to transform that abstract idea into a patent-eligible invention” The subject matter is ineligible for a patent, but computer-related inventions not drawn to an abstract idea may still be eligible.

11 Alice Corp. v. CLS Bank, 6/19/14 Analysis “As stipulated, the claimed method requires the use of a computer to create electronic records, track multiple transactions, and issue simultaneous instructions; in other words, ‘[t]he computer is itself the intermediary.’” The claims here do nothing more than “simply instruct the practitioner to implement the abstract idea of intermediated settlement on a generic computer.”

12 Alice Corp. v. CLS Bank, 6/19/14 Rationale “Laws of nature, natural phenomena, and abstract ideas are the basic tools of scientific and technological work. “Monopolization of those tools through the grant of a patent might tend to impede innovation more than it would tend to promote it, thereby thwarting the primary object of the patent laws.” [citations and interior quotes eliminated]

13 The Court Distrusts the Patent System Ineligibility is linked to purported preemption of scientific research and discovery by patent claims that are said to be drawn to laws of nature, natural phenomena, and abstract ideas In determining eligibility, the specificity of the claims is ignored by generalizing them into an abstraction and then using the abstraction as a core that is ignored in determining whether “significantly more” than the abstraction is present—a subjective exercise that eviscerates the claims

14 Ironically, the Court rewards the clever draftsman “This Court has long warned against interpreting §101 in ways that make patent eligibility depend simply on the draftsman’s art.” Alice, quoting from Prometheus [interior quotes, ellipses omitted] Claims that are atomized into smaller parts, that include more hardware, more non-natural parts, more physical effects, and more detail are likely to be more successful. See Ultramercial v. Hulu, 722 F.3d 1335 (Fed. Cir. 6/21/13)(example of patent claims found not abstract, and in an opinion by J. Lourie, who is hostile to eligibility)

15 What to do?—Pass a law to override Prometheus Add a new sentence at the end of section 101 of 35 U.S.C.: Claimed subject matter that provides a useful, concrete, and tangible result shall not be denied eligibility for a patent on the ground that it is directed to a law of nature, natural phenomenon, or abstract idea, and shall be evaluated in accordance with the other provisions of this title.

Thank you.